Brief: Vyne Therapeutics Announces Dosing Of First Participants In Phase 1a Trial Of Novel BD2-Selective Bet Inhibitor VYN202

YARROW BIOSCIENCE

13/06/2024 14:23

June 13 (Reuters) - Vyne Therapeutics Inc  VYNE.O :
    * VYNE THERAPEUTICS ANNOUNCES DOSING OF FIRST PARTICIPANTS
IN
PHASE 1A TRIAL OF NOVEL BD2-SELECTIVE BET INHIBITOR VYN202
    * VYNE THERAPEUTICS ANNOUNCES DOSING OF FIRST PARTICIPANTS
IN
PHASE 1A TRIAL OF NOVEL BD2-SELECTIVE BET INHIBITOR VYN202
    * VYNE THERAPEUTICS INC: TOP-LINE DATA EXPECTED IN 2H'24

Source text for Eikon:  ID:nGNX6Q5Z9l 
Further company coverage:  VYNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))